Boston Scientific Expects Synergy To Dominate Drug-Eluting Stents In US

Boston Scientific wants to expand the lead against other stents used by interventional cardiologists with the launch of its Synergy drug-eluting stent that they expect will become the workhorse of the industry to handle a broad range of surgeries to treat coronary artery disease. "Our belief is that the target for Synergy is [the] entire market," says Boston Scientific's senior VP and president of its interventional cardiology unit.